Cholesterol Stocks Clobbered: Good Clinical Results But High Expectations
Upbeat Drug Study Data from an Amgen Cholesterol Trial but Stocks are Clobbered Because of Higher Expectations LDL cholesterol is a Toxic Risk Factor Results from a long-term study on the efficacy of a new generation of LDL cholesterol reducing drugs fell short of expectations and clobbered...
Biotech Rally Clipped by Trump Tweet; ACA Makeover Creates Uncertainty…Update-1
Update-1... 10:45 am PST Biotech Rally Resumes tweets on drug pricing are apparently forgotten XBI up 2.63%, IBB up 1.6% Green screen day Smaller cap, clinical stage stocks dominate winners. =========== Trump Tweet Clips Biotech Rally-Drug Pricing Rhetoric Clouds Prospects Again "Trumpcare"...
Rayno BioBeat 2017 #2: Biotech Breakthrough Rally
2017 Biotech Breakthrough on a Green Screen Day Biotech stocks got a second wind today and the 2017 rally broke through recent tops that have been strong resistance. Our favorite trading pick the XBI soared 4.82% to $70.48 breaking through the September top and 19% up YTD. The large cap IBB...
Biotech ETFs: Fidelity Biotech Fund Outperforms IBB but XBI is Still the Leader
Fidelity Biotech Portfolio (FBIOX) Is Beginning to Show Benefits of Active Management Biotech stocks have outperformed the market YTD despite a bit of a sell-off recently. During the bubblicious momentum days of 2015 when biotech was on a tear major biotech ETFs outperformed mutual funds. After...
Rayno Biopharma Portfolio Update: BLUE FMI IBB…Update-1
Update-1... 2/22/17 Dow closed at a record 20,775.6 with energy the big loser, healthcare down 0.19% and NASDAQ flattish. Biotech stocks sold off with the IBB down 0.85% after hitting $296 near a 52 week high last Thursday. XBI was hit harder down 1.77% to $67.79. Large caps were mainly in the...